Epifocal dinitrochlorobenzene therapy in malignant melanoma (experience during the last eight years).
A total of 50 patients with primary malignant melanomas received epifocal DNCB therapy. In 46 cases the tumors disappeared completely. Therefore, we partly refrained from excision of the treated area. Only 4 melanomas of great thickness did not respond satisfactorily. In the treatment of cutaneous metastases, however, remission was achieved only in one case. The 5-year survival rate for primary tumors was 87.8 +/- 10.55%. We believe that DNCB therapy is indicated especially in superficially growing melanomas, patients with limited operability, or flat melanomas of acral localization, where the patients are spared mutilating operations.
D004137:Dinitrochlorobenzene / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008875:Middle Aged; D009578:Nitrobenzenes / Q000008:administration & dosage*; D009824:Ointments; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D013997:Time Factors
D004137:Dinitrochlorobenzene; D009578:Nitrobenzenes; D009824:Ointments